Response from IR:
Question, ...
"Hello, Chris. In the AGM, 31 minutes into it, Don stated that Zenith is no longer pursuing TNBC because someone else got there first. The free market economy encourages competition does it not?
If Zenith is no longer in the TNBC trial there has to be a better explanation than what is stated by Don.
Reference: TNBC; presumably NCT03901469 (phase 2, recruiting, 179 patients)
Looking forward to an explanation or clarification, with thanks."
Response from IR,
"Thank you for your question. As you know, Zenith has many active clinical programs, and ZEN-3694 has shown promise in a number of indications. While we hope that each of these indications proves successful, we expect that not all of them will be. The decisions about which indications to pursue are always multi-faceted and carefully considered. Factors that contribute to our decisions include clinical results, market conditions, resource allocations, regulatory pathways, partnering opportunities, and existing treatment options, among others.
Ultimately, our goal is to develop therapies that benefit the most people, and provide the best possible return on investment for our shareholders."
Koo
